For indications like Parkinson’s disease (PD) that rely on subjective reporting measures, the placebo response is a major problem:

A problem that snowballs into higher development costs, longer timelines and the premature abandonment of development programs.

And, ultimately, a lack of cure for patients with PD.

In this guide, we discuss:

• How the placebo problem uniquely plays out in PD patients
• Historical approaches to managing the placebo response in PD
• A new strategy to work towards successfully delivering a cure